The National Institute of Allergy and Infectious Diseases (NIAID) is offering grants to institutions and organizations for research on Fc-dependent, antibody-mediated killing of cells in immune pathologies. This grant aims to study variables affecting efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), both in vitro and in vivo. Awardees will collaborate in annual meetings to accelerate the development of mechanistic models. The research outcomes could enhance the design of ablative antibody therapeutics and vaccines that elicit efficient antibody responses. This Funding Opportunity Announcement utilizes the U01 grant mechanism, and complementary research can be supported through the R21 mechanism.
Opportunity ID: 309428
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AI-18-042 |
| Funding Opportunity Title: | Fc-Dependent Mechanisms of Antibody-Mediated Killing (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 05, 2018 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Feb 01, 2019 |
| Current Closing Date for Applications: | Feb 01, 2019 |
| Archive Date: | Mar 09, 2019 |
| Estimated Total Program Funding: | $2,000,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Independent school districts Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Public and State controlled institutions of higher education Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP), both in vitro and in vivo. U01 awardees will be expected to attend annual Program Progress/Steering Committee meetings and present progress to fellow awardees and to NIAID program staff. The goal of the meetings is to facilitate collaborations between funded investigators and to accelerate development of mechanistic models that incorporate the collective findings of this program. Advances in our understanding of these Fc-dependent killing mechanisms will inform more efficient design and optimization of ablative antibody therapeutics and may also inform design of vaccines that preferentially elicit ADCC- or ADCP-efficient antibody responses. This FOA uses the U01 grant mechanism, while the companion FOA, PA-19-xxx, uses the R21 mechanism. High risk/high reward projects with limited preliminary data or utilize existing data may be most appropriate for the R21 mechanism. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-042.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00245410 | Jan 02, 2019 | Feb 01, 2019 | View |
Package 1
Mandatory forms
309428 RR_SF424_2_0-2.0.pdf
309428 PHS398_CoverPageSupplement_4_0-4.0.pdf
309428 RR_OtherProjectInfo_1_4-1.4.pdf
309428 PerformanceSite_2_0-2.0.pdf
309428 RR_KeyPersonExpanded_2_0-2.0.pdf
309428 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
309428 RR_Budget_1_4-1.4.pdf
309428 RR_SubawardBudget30_1_4-1.4.pdf
309428 PHS398_ModularBudget_1_2-1.2.pdf
309428 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
